Intravenous Immunoglobulin Market cover

Intravenous Immunoglobulin Market by Applications (Immunodeficiency Diseases, Hypogammaglobulinemia, CIPD, Myasthenia, Guillain-Barre Syndrome, Gravis, ITP, Kawasaki Disease, Multifocal Motor Neuropathy, Congenital Aids, Chronic Lymphocytic Leukemia, and Others), Routes of Administration (Subcutaneous and Intravenous), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: CG-2175
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 193
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global intravenous immunoglobulin market size is estimated to register a high CAGR during the forecast period, 2021–2028. The growth of the market is accredited to the rising incidences of immunodeficiency diseases and increasing geriatric population.

Intravenous Immunoglobulin Market summary

Intravenous immunoglobulin (IVIG), a widely approved antibodies proteins, is used intravenously to strengthen the compromised immune system to fight various infections and diseases. It is a biological agent which is used to cure and treat various health conditions such as inflammatory states, infectious, and autoimmune. As per a report published by the World Health Organization (W.H.O.), there are over 50 several primary immune deficiency diseases with specific antibody deficiency and others. Primary immune deficiency consists of 176 various types of hereditary disorders and approximately 5 million patients are suffering from the deficiency worldwide, according to a report by U.S. National Library of Medicine and National Institute of Health.

The high demand for IVIG therapies is increasing as it offers the most effective treatment and is the only option available in the market. Furthermore, less physical activities, lifestyle habits, high alcohol consumption, and consumption of saturated fats salt, & sugars have caused an increase in the incidence of the infectious diseases. Global geriatric population is on rise and presents a key aspect for the market expansion. The number of population aged over 65 in the U.S. was approximately 45 million in 2014 and is expected to be over 97 million by 2060 according to a report by United States Census Bureau.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising geriatric population, rising incidences of immunodeficiency diseases, and increasing use of off-label indications are the main drivers of the market. 
  • Growing incidences of lifestyle-associated disorders such as antibody and obesity deficiency disorders are the factors expected to drive the market growth.
  • Increasing number of incidence of immunodeficiency disorders is the cause for the development of IVIG preparations which is a key factor to provide growth opportunities to the market.
  • Rising number of intravenous product approvals and expansion of clinical trials of several treatment drugs for the disease are likely to propel the market growth.  
  • Growing awareness and increasing healthcare expenditure of consumers due to rising number of health-conscious population worldwide are expected to further spur the market growth.
  • Available of several alternative for the treatment of immunodeficiency diseases acts as a key restraining factor, which is expected to hamper the market growth.

Scope of the Report                         

The report on the global intravenous immunoglobulin market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Intravenous Immunoglobulin Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Applications (Immunodeficiency Diseases, Hypogammaglobulinemia, CIPD, Myasthenia, Guillain-Barre Syndrome, Gravis, ITP, Kawasaki Disease, Multifocal Motor Neuropathy, Congenital Aids, Chronic Lymphocytic Leukemia, and Others) and Routes of Administration (Intravenous and Subcutaneous)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

LFB Biotechnologies; Baxter International Inc.; Octapharma AG; Biotest AG; Grifols S.A.; China Biologics Products, Inc.; Kedrion Biopharma; and BDI Pharma Inc.; and CSL Behring

 

Market Segment Insights

Hypogammaglobulinemia segment is expected to grow at a rapid pace

Based on applications, the global intravenous immunoglobulin market is divided into immunodeficiency diseases, hypogammaglobulinemia, CIPD, myasthenia, guillain-barre syndrome, gravis, ITP, kawasaki disease, multifocal motor neuropathy, congenital aids, chronic lymphocytic leukemia, and others. The hypogammaglobulinemia segment is expected to grow at a rapid pace in the market during the forecast period owing to the rising incidences of immunodeficiency diseases globally. However, the kawasaki disease segment is anticipated to exhibit a high CAGR during the forecast period due to increasing incidence of kawasaki disease in children and high demand of IVIG treatment.

Intravenous Immunoglobulin Market application

Subcutaneous segment is projected to expand at a considerable CAGR

On the basis of routes of administration, the market is bifurcated into subcutaneous and intravenous. The subcutaneous segment is projected to expand at a considerable CAGR during the forecast period due to preference of subcutaneous immunoglobulin for home based immunotherapy. On the other hand, the intravenous segment is anticipated to account for a key share of the market owing to increasing number of clinical trials and intravenous product approvals.

North America is anticipated to constitute a key market share

In terms of regions, the global intravenous immunoglobulin market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market in the coming years owing to increasing awareness about immunodeficiency diseases and increasing healthcare expenditure in the region. The market of Asia Pacific, meanwhile, is expected to grow at a healthy growth rate during the forecast period due to growing incidences of immune disorders and improving healthcare facilities in the region.

Intravenous Immunoglobulin Market region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Intravenous Immunoglobulin Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Intravenous Immunoglobulin Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Intravenous Immunoglobulin Market - Supply Chain
  4.5. Global Intravenous Immunoglobulin Market Forecast
     4.5.1. Intravenous Immunoglobulin Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Intravenous Immunoglobulin Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Intravenous Immunoglobulin Market Absolute $ Opportunity
5. Global Intravenous Immunoglobulin Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Intravenous Immunoglobulin Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Intravenous Immunoglobulin Demand Share Forecast, 2019-2026
6. North America Intravenous Immunoglobulin Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Intravenous Immunoglobulin Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Intravenous Immunoglobulin Demand Share Forecast, 2019-2026
7. Latin America Intravenous Immunoglobulin Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Intravenous Immunoglobulin Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Intravenous Immunoglobulin Demand Share Forecast, 2019-2026
8. Europe Intravenous Immunoglobulin Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Intravenous Immunoglobulin Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Intravenous Immunoglobulin Demand Share Forecast, 2019-2026
9. Asia Pacific Intravenous Immunoglobulin Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Intravenous Immunoglobulin Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Intravenous Immunoglobulin Demand Share Forecast, 2019-2026
10. Middle East & Africa Intravenous Immunoglobulin Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Intravenous Immunoglobulin Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Intravenous Immunoglobulin Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Intravenous Immunoglobulin Market: Market Share Analysis
  11.2. Intravenous Immunoglobulin Distributors and Customers
  11.3. Intravenous Immunoglobulin Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. LFB Biotechnologies
     11.4.2. Baxter International Inc.
     11.4.3. Octapharma AG
     11.4.4. Biotest AG
     11.4.5. Grifols S.A.
     11.4.6. China Biologics Products, Inc.
     11.4.7. Kedrion Biopharma
     11.4.8. B

Segments Covered in the Report

The global intravenous immunoglobulin market has been segmented on the basis of

Applications

  • Immunodeficiency Diseases
  • Hypogammaglobulinemia
  • CIPD
  • Myasthenia
  • Guillain-Barre Syndrome
  • Gravis
  • ITP
  • Kawasaki Disease
  • Multifocal Motor Neuropathy
  • Congenital Aids
  • Chronic Lymphocytic Leukemia
  • Others

Routes of administration

  • Subcutaneous
  • Intravenous

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • LFB Biotechnologies
  • Baxter International Inc.
  • Octapharma AG
  • Biotest AG
  • Grifols S.A.
  • China Biologics Products, Inc.
  • Kedrion Biopharma
  • BDI Pharma Inc.
  • CSL Behring

Key players competing in the intravenous immunoglobulin market are LFB Biotechnologies; Baxter International Inc.; Octapharma AG; Biotest AG; Grifols S.A.; China Biologics Products, Inc.; Kedrion Biopharma; and BDI Pharma Inc.; and CSL Behring. The key market players are participating in the activities such as mergers and acquisitions, research and development, and collaborations to enhance their market position. For instance, China Biologics entered into a collaboration with Xinjiang Deyuan Bioengineering Co., Ltd for sourcing raw material for the production of IVIG products, in September 2015.

Intravenous Immunoglobulin Market keyplayers

Buy Report